• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OVID

    Ovid Therapeutics Inc.

    Subscribe to $OVID
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: ovidrx.com

    Peers

    $AQST

    Recent Analyst Ratings for Ovid Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    See more ratings

    Ovid Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    Ovid Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ovid Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform

      6/18/24 7:38:14 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Ovid Therapeutics with a new price target

      B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/30/24 8:03:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ovid Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/29/24 7:56:55 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Ovid Therapeutics with a new price target

      Wedbush initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00

      4/5/24 7:29:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Ovid Therapeutics with a new price target

      BTIG Research initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $11.00

      12/21/23 6:49:27 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Ovid Therapeutics with a new price target

      Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00

      10/13/23 7:20:47 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Ovid Therapeutics with a new price target

      Citigroup reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $4.00 from $4.50 previously

      8/25/21 11:11:04 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Ovid Therapeutics from Buy to Neutral and set a new price target of $4.00

      4/20/21 7:29:57 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS Group reiterated coverage on Ovid Therapeutics with a new price target

      UBS Group reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $5.00 from $4.00 previously

      3/4/21 7:49:31 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Ovid Therapeutics from Outperform to Sector Perform and set a new price target of $5.00

      3/3/21 11:58:56 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ovid Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      1/29/25 9:18:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/20/24 5:22:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ovid Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Ovid Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Ovid Therapeutics Inc. SEC Filings

    See more
    • SEC Form 4 filed by Director Papadopoulos Stelios

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:44:34 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Papadopoulos Stelios claimed ownership of 200,000 shares (SEC Form 3)

      3 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:42:41 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBFO Rona Jeffrey A sold $2,185 worth of shares (3,902 units at $0.56), decreasing direct ownership by 5% to 67,973 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/28/25 4:15:08 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and COO Alexander Margaret A. sold $2,956 worth of shares (5,279 units at $0.56), decreasing direct ownership by 7% to 73,406 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/28/25 4:15:10 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO Levin Jeremy M

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/24/25 7:55:09 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and COO Alexander Margaret A. was granted 43,750 shares, increasing direct ownership by 125% to 78,685 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/24/25 7:55:05 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBFO Rona Jeffrey A was granted 43,750 shares, increasing direct ownership by 156% to 71,875 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/24/25 7:55:07 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      1/29/25 9:18:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Friedman Bart

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      12/16/24 4:15:19 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fitzgerald Kevin Joseph

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      12/16/24 4:15:20 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at  investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da

      4/2/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of

      3/11/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

      NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 days. About

      2/27/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

      NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation. About Ovid TherapeuticsOvid Therapeutics Inc. is a

      2/5/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

      Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory status epilepticus to be presented NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions

      12/2/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

      A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators and their broad therapeutic potential.Ovid and Graviton are pausing the initiation of a Phase 2 study of OV888/GV101 to evaluate emerging insights from two recently completed competitor trials in cereb

      11/12/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Host Investor Event

      NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously. The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid's KCC2 portfolio. Company management will provide updates on the po

      10/31/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

      Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329's potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for completion in late 2024 and will evaluate safety and two biomarkers for target engagement and evidence of clinical effect NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:O

      9/26/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

      NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy. "Ovid's programs are advancing rapidly, and we are taking the critical steps needed for sustainable growth. Meg has proven to be a strong leader, driving change and delivering value across multiple

      9/11/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:14:40 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Ovid Therapeutics Inc.

      PRE 14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:09:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Ovid Therapeutics Inc.

      10-K/A - Ovid Therapeutics Inc. (0001636651) (Filer)

      4/30/25 4:06:12 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Ovid Therapeutics Inc.

      10-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      3/11/25 9:08:46 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      3/11/25 8:51:30 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      3/5/25 4:08:20 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      2/13/25 5:15:24 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ovid Therapeutics Inc.

      10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)

      11/12/24 8:07:17 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      11/12/24 8:03:59 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      9/11/24 4:57:01 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ovid Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

      NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

      8/8/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

      Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d

      7/23/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

      Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy OfficerOvid streamlined G&A infrastructure to improve operational efficiency and reduce costs NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic

      6/28/23 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

      NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors. "We are very pleased to have Kevin join our Board of Directors. His experience transforming state-of-the-art science and novel platform technologies into commercial medicines will provide valuable perspective for Ovid's neuroscience development programs," said Jeremy Levin, D.Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. "Kevin's expertise across small molecule an

      10/7/21 8:30:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

      New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. "Ovid is building the intellectual and scientific platform to tackle the big questions in neuroscience so as to develop new medicines. To that end, Ovid is deepening the expertise and strengths of our Scientific Advisory Board by the addition of key leaders in specific areas. According

      5/26/21 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sales if soticlestat is commercializedEnding Q1'21 cash and cash equivalents balance of $233.1 million and reduced cash burn supports prioritization of resources to advance robust early-stage neuroscience pipeline and explore full ecosystem of complementary external innovation Company is actively pursuing business development opportunities to advance its early-stage neuroscience pipeline and is planning to evaluate clinic

      5/13/21 4:05:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

      NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board. "We welcome Professor Robert Langer, who has joined Ovid as the new Chair of our Scientific Advisory Board," said Amit Rakhit, M.D., MBA, President, Ovid Therapeutics. "Bob will help guide Ovid's strategy to tackle opportunities and scientific questions underlying disorders in the brain. His perspective will be invaluable as we advance our pipeline of next-genera

      4/20/21 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Ovid Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 6:01:44 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 4:39:42 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/24 4:15:31 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/24 11:10:32 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/12/24 6:06:38 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ovid Therapeutics Inc.

      SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

      1/29/24 5:25:49 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ovid Therapeutics Inc.

      SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

      7/31/23 5:21:08 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/23 4:01:14 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/13/23 10:28:21 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ovid Therapeutics Inc.

      SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/10/23 4:00:19 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care